Stryker Corporation $SYK Stock Holdings Decreased by Phoenix Financial Ltd.

Phoenix Financial Ltd. reduced its position in shares of Stryker Corporation (NYSE:SYK) by 23.2% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 19,147 shares of the medical technology company’s stock after selling 5,798 shares during the quarter. Phoenix Financial Ltd.’s holdings in Stryker were worth $7,092,000 at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. Paragon Private Wealth Management LLC increased its holdings in shares of Stryker by 40.0% in the 3rd quarter. Paragon Private Wealth Management LLC now owns 2,708 shares of the medical technology company’s stock valued at $1,001,000 after purchasing an additional 774 shares during the period. KPP Advisory Services LLC grew its position in Stryker by 28.1% during the third quarter. KPP Advisory Services LLC now owns 1,688 shares of the medical technology company’s stock valued at $624,000 after purchasing an additional 370 shares in the last quarter. Bank of Jackson Hole Trust increased its stake in Stryker by 2.8% in the 3rd quarter. Bank of Jackson Hole Trust now owns 2,070 shares of the medical technology company’s stock valued at $765,000 after buying an additional 57 shares during the period. Chilton Capital Management LLC lifted its position in Stryker by 1.1% in the 3rd quarter. Chilton Capital Management LLC now owns 81,152 shares of the medical technology company’s stock worth $29,999,000 after buying an additional 910 shares in the last quarter. Finally, Alta Advisers Ltd boosted its stake in shares of Stryker by 6.1% during the 3rd quarter. Alta Advisers Ltd now owns 1,731 shares of the medical technology company’s stock valued at $640,000 after buying an additional 100 shares during the period. 77.09% of the stock is owned by institutional investors and hedge funds.

Stryker Stock Performance

Shares of NYSE SYK opened at $357.16 on Tuesday. Stryker Corporation has a 12 month low of $329.16 and a 12 month high of $406.19. The company has a market cap of $136.59 billion, a P/E ratio of 46.93, a P/E/G ratio of 2.28 and a beta of 0.89. The business’s 50 day moving average is $359.72 and its two-hundred day moving average is $372.41. The company has a quick ratio of 1.13, a current ratio of 1.85 and a debt-to-equity ratio of 0.68.

Stryker (NYSE:SYK) last announced its quarterly earnings data on Friday, October 31st. The medical technology company reported $3.19 EPS for the quarter, beating analysts’ consensus estimates of $3.13 by $0.06. Stryker had a net margin of 12.07% and a return on equity of 24.07%. The business had revenue of $6.06 billion during the quarter, compared to analyst estimates of $6.04 billion. During the same quarter in the prior year, the business earned $2.87 earnings per share. The firm’s revenue for the quarter was up 10.2% on a year-over-year basis. On average, equities analysts expect that Stryker Corporation will post 13.47 EPS for the current year.

Stryker Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, January 30th. Stockholders of record on Wednesday, December 31st will be paid a $0.88 dividend. The ex-dividend date is Wednesday, December 31st. This represents a $3.52 annualized dividend and a dividend yield of 1.0%. This is an increase from Stryker’s previous quarterly dividend of $0.84. Stryker’s dividend payout ratio is currently 46.25%.

Wall Street Analyst Weigh In

A number of research analysts have commented on SYK shares. Wells Fargo & Company boosted their target price on Stryker from $452.00 to $456.00 and gave the company an “overweight” rating in a research note on Friday, November 14th. The Goldman Sachs Group set a $399.00 price target on Stryker in a report on Friday, January 9th. Raymond James Financial upgraded Stryker from a “market perform” rating to an “outperform” rating and set a $418.00 price objective on the stock in a report on Tuesday, January 6th. Weiss Ratings reiterated a “hold (c+)” rating on shares of Stryker in a research note on Monday, December 22nd. Finally, UBS Group set a $408.00 target price on shares of Stryker in a research report on Monday, October 13th. Fourteen analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $430.00.

Insider Transactions at Stryker

In related news, Director Ronda E. Stryker sold 276,173 shares of the business’s stock in a transaction on Thursday, November 6th. The stock was sold at an average price of $353.28, for a total value of $97,566,397.44. Following the sale, the director owned 2,702,108 shares of the company’s stock, valued at $954,600,714.24. The trade was a 9.27% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CAO William E. Berry, Jr. sold 1,953 shares of the business’s stock in a transaction on Friday, November 14th. The shares were sold at an average price of $365.49, for a total transaction of $713,801.97. Following the completion of the sale, the chief accounting officer owned 2,833 shares in the company, valued at $1,035,433.17. This represents a 40.81% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 522,118 shares of company stock valued at $185,381,932. Corporate insiders own 5.90% of the company’s stock.

Stryker Company Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.